Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SOL-257
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SOLA Biosciences Presented Positive ALS Animal Efficacy Data of SOL-257
Details : SOLA has developed an innovative chaperone technology (JUMP70) to selectively eliminate disease-causing misfolded proteins using the patients' own chaperones. SOLA has developed nine gene therapy candidates incorporating JUMP70 to address conformational ...
Product Name : SOL-257
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : SOL-257
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable